Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation.

Literature DB >> 21075304

STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation.

Ann Mullally¹, Benjamin L Ebert.

Abstract

Entities: Chemical Disease Gene Species

Year: 2010 PMID： 21075304 PMCID： PMC3001244 DOI： 10.1016/j.ccr.2010.10.037

Source DB: PubMed Journal: Cancer Cell ISSN： 1535-6108 Impact factor: 31.743

Keyword Cloud
References

× No keyword cloud information.

10 in total

1. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

Authors: Linda M Scott; Mike A Scott; Peter J Campbell; Anthony R Green
Journal: Blood Date: 2006-06-13 Impact factor: 22.113

2. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Authors: Peter J Campbell; Linda M Scott; Georgina Buck; Keith Wheatley; Clare L East; Joanne T Marsden; Audrey Duffy; Elaine M Boyd; Anthony J Bench; Mike A Scott; George S Vassiliou; Donald W Milligan; Steve R Smith; Wendy N Erber; David Bareford; Bridget S Wilkins; John T Reilly; Claire N Harrison; Anthony R Green
Journal: Lancet Date: 2005-12-03 Impact factor: 79.321

Review 3. Myeloproliferative disorders.

Authors: Ross L Levine; D Gary Gilliland
Journal: Blood Date: 2008-09-15 Impact factor: 22.113

4. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

Authors: Chloé James; Valérie Ugo; Jean-Pierre Le Couédic; Judith Staerk; François Delhommeau; Catherine Lacout; Loïc Garçon; Hana Raslova; Roland Berger; Annelise Bennaceur-Griscelli; Jean Luc Villeval; Stefan N Constantinescu; Nicole Casadevall; William Vainchenker
Journal: Nature Date: 2005-04-28 Impact factor: 49.962

Review 9. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

Authors: A Tefferi
Journal: Leukemia Date: 2010-04-29 Impact factor: 11.528

10. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.

Authors: Mark A Dawson; Andrew J Bannister; Berthold Göttgens; Samuel D Foster; Till Bartke; Anthony R Green; Tony Kouzarides
Journal: Nature Date: 2009-09-27 Impact factor: 49.962

10 in total

STATistical power of clonal analysis: differential STAT1 pathway activation downstream of the JAK2V617F mutation.

1. Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

2. Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

Review 3. Myeloproliferative disorders.

4. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera.

5. A gain-of-function mutation of JAK2 in myeloproliferative disorders.

6. Host genetic variation contributes to phenotypic diversity in myeloproliferative disorders.

7. STAT1 promotes megakaryopoiesis downstream of GATA-1 in mice.

8. Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling.

Review 9. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1.

10. JAK2 phosphorylates histone H3Y41 and excludes HP1alpha from chromatin.